Information non disponible
- Bouaou, Ania MelissaEmployéaniafirstname.lastname@example.org
Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021Article de revue
Cancer, 129 (20), 2023.
Management of Oligometastatic Breast Cancer: An Expert Committee's OpinionArticle de revue
Curr Oncol, 30 (2), 2023.
Perceived guideline clarity impacts guideline-concordant care for breast cancer screening in women age 40-49Article de revue
BMC Womens Health, 23 (1), 2023.
Determinants of guideline-concordant breast cancer screening by family physicians for women aged 40-49 years: a qualitative analysisArticle de revue
CMAJ Open, 10 (4), 2022.
Fragility index of trials supporting approval of anti-cancer drugs in common solid tumoursArticle de revue
Cancer Treat Rev, 94 , 2021.
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, ExperienceArticle de revue
Oncologist, 26 (4), 2021.
Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid CancersArticle de revue
J Cancer, 12 (14), 2021.
Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold?Article de revue
JAMA Oncol, 7 (8), 2021.
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designationsArticle de revue
Cancer Med, 10 (16), 2021.
Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology TrialsArticle de revue
J Natl Compr Canc Netw, 19 (12), 2021.